News Summary

Boston-based Syntis Bio has introduced an innovative obesity treatment with its lead program, SYNT-101. This once-daily pill aims to mimic the effects of gastric bypass surgery by blocking nutrient absorption in the upper small intestine, providing a unique alternative to the widely used GLP-1 agonists. Early data presented at the European Congress on Obesity and Weight Management demonstrate that the approach is safe and potentially effective in suppressing hunger. Syntis Bio’s CEO and cofounder, Rahul Dhanda, highlighted the importance of developing more effective obesity treatments. The pill temporarily coats the upper small intestine, redirecting nutrient absorption and triggering satiety hormones. This approach could offer a promising option for those seeking weight loss solutions without surgery.